In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Microarray-Based Phospho-Proteomic Profiling of Complex Biological Systems

    Final Number:
    1636

    Authors:
    C. Rory Goodwin MD, PhD; Crystal Woodard; Xin Zhou; Alessandro Olivi MD; Jonathan Pevsner; Heng Zhu; John Laterra MD, PhD

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2015 Annual Meeting

    Introduction: Protein phosphorylation influences ~30% of the proteome and regulates fundamental cellular processes such as cell proliferation, migration, and angiogenesis. Protein microarray technology has been successfully used for identifying substrates of purified activated kinases. In this study, we describe the novel application of protein microarray technology to globally assess the influence of PTEN function on the phospho-kinome of glioma cells in vitro and glioma xenografts in vivo.

    Methods: We utilized a glioma cell line engineered to express PTEN via a tet-on promoter system (U87-tetPTEN) and validated results in clinical pathological specimens. Whole cell (in vitro) or whole tumor (in vivo) lysates obtained from control and doxycycline-treated conditions were incubated on human protein microarrays in the presence of 32P-?-ATP and kinases that demonstrated a significant reduction in phosphorylation in the PTEN induced group (doxycycline-treated) were identified.

    Results: PTEN was robustly increased, Akt phosphorylation was inhibited by ~90% after incubating cells with doxycycline in vitro for 24 hours. PTEN reconstitution inhibited cell growth in vitro and treating animals following cell implantation with doxycycline arrested the growth of subcutaneous tumor xenografts. Using the protein microarray, PTEN reconstitution decreased the phosphorylation of 135 protein targets in vitro and 103 protein targets in vivo. Twenty clinical WHO grade IV gliomas were obtained and stratified by semi-quantitative immunoblot analysis into high phospho-Akt expressers and low phospho-Akt expressers. Tumor lysates were analyzed by immunoblot for five phospho-proteins shown to be PTEN-regulated by the protein microarray assays. As predicted by microarray analysis, in comparison to the high phospho-Akt glioblastomas, the low phospho-Akt glioblastomas had statistically significantly lower phosphorylated forms of the kinases.

    Conclusions: Thus, microarray analysis could be potentially used to predict associations between Akt activity and protein phosphorylation in clinical specimens. Our findings identify a novel microarray-based method for assessing intracellular signaling events applicable to human oncogenesis.

    Patient Care: Our findings identify a novel microarray-based method for assessing intracellular signaling networks that will increase our understanding of oncogenesis and aid in the advancement of novel cancer therapeutics.

    Learning Objectives: By the end of this session, participants should be able to discuss how microarray-based technologies can be used to assessing intracellular signaling events applicable to human oncogenesis.

    References: References 1. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nature biotechnology. Mar 2003;21(3):255-261. 2. Newman RH, Hu J, Rho HS, et al. Construction of human activity-based phosphorylation networks. Molecular systems biology. 2013;9:655. 3. Woodard CL, Goodwin CR, Wan J, et al. Profiling the Dynamics of a Human Phosphorylome Reveals New Components in HGF/c-Met Signaling. PloS one. 2013;8(9):e72671. 4. Ptacek J, Devgan G, Michaud G, et al. Global analysis of protein phosphorylation in yeast. Nature. Dec 1 2005;438(7068):679-684. 5. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Advances in cancer research. 2005;94:29-86. 6. Goodwin CR, Lal B, Ho S, et al. PTEN reconstitution alters glioma responses to c-Met pathway inhibition. Anti-cancer drugs. Oct 2011;22(9):905-912.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy